Introcaso Camille E, Hess Stephen D, Kamoun Malek, Ubriani Ravi, Gelfand Joel M, Rook Alain H
Department of Dermatology, The University of Pennsylvania, Philadelphia, Pennsylvania, USA.
J Am Acad Dermatol. 2005 Sep;53(3):428-34. doi: 10.1016/j.jaad.2005.06.001.
Because there are currently many effective therapies available for Sézary syndrome, close monitoring of disease progression is required in order for a clinician to know when to institute or change an intervention. It has been our clinical experience that changes in patients' CD4+CD26- T-cell populations of peripheral blood lymphocytes herald changes in their clinical status.
Our purpose was to evaluate whether a change in patients' CD4+CD26- population of T cells presages a change in their clinical status. We also sought to investigate the association between a change in T-cell populations that are CD4+CD7-, CD8+, CD56+, and the CD4+/CD8+ T-cell ratio and a change in the patient's clinical status.
We conducted a retrospective chart review analysis of 21 patients with Sézary syndrome who had flow cytometry, usually including levels of CD4+CD26-, CD4+CD7-, CD8+, CD56+, and CD4+/CD8+ ratios measured at two time periods, 12 weeks apart.
We report two cases in which changes in patients' clinical status were preceded by several weeks by a change in their CD4+CD26- level. We report weak associations between a decreasing CD4+CD26- T-cell population, a decreasing CD4+CD7- population, an increasing CD56+ population, and an improving clinical status. We also report stronger associations between both a decreasing CD8+ population and an increasing CD4+/CD8+ ratio and a worsening clinical status.
The study was limited by the number of patients and the time period over which the study was conducted. In addition, varying configurations of CD4+CD26- T-cell populations were observed that may have limited the utility of this measurement.
Flow cytometry assays of patients' blood and, in particular, measurement of the CD4+CD26- population of lymphocytes over time may be a valuable tool for monitoring patients with Sézary syndrome. There exist varying configurations of CD26 T lymphocytes that may cause differences in standards for what is considered positive and negative between observers. Further prospective analysis involving larger groups of patients is recommended.
由于目前有多种有效的疗法可用于治疗 Sézary 综合征,因此临床医生需要密切监测疾病进展,以便知道何时开始或改变干预措施。我们的临床经验表明,患者外周血淋巴细胞中 CD4+CD26- T 细胞群体的变化预示着其临床状态的改变。
我们的目的是评估患者 CD4+CD26- T 细胞群体的变化是否预示着其临床状态的改变。我们还试图研究 CD4+CD7-、CD8+、CD56+ T 细胞群体的变化以及 CD4+/CD8+ T 细胞比值与患者临床状态变化之间的关联。
我们对 21 例 Sézary 综合征患者进行了回顾性病历分析,这些患者接受了流式细胞术检测,通常包括在两个相隔 12 周的时间段测量 CD4+CD26-、CD4+CD7-、CD8+、CD56+水平以及 CD4+/CD8+比值。
我们报告了两例患者,其临床状态的改变在数周前先出现 CD4+CD26-水平的变化。我们报告 CD4+CD26- T 细胞群体减少、CD4+CD7-群体减少、CD56+群体增加与临床状态改善之间存在弱关联。我们还报告 CD8+群体减少和 CD4+/CD8+比值增加与临床状态恶化之间存在更强的关联。
该研究受到患者数量和研究进行时间段的限制。此外,观察到 CD4+CD26- T 细胞群体存在不同的构成形式,这可能限制了该测量方法的实用性。
对患者血液进行流式细胞术检测,尤其是随时间测量淋巴细胞的 CD4+CD26-群体,可能是监测 Sézary 综合征患者的有价值工具。CD26 T 淋巴细胞存在不同的构成形式,这可能导致观察者之间对阳性和阴性标准的判断存在差异。建议进一步开展涉及更大患者群体的前瞻性分析。